Gyre Therapeutics Inc. (GYRE)
NASDAQ · Healthcare
Gyre Therapeutics Inc. EBITDA 2009–2025
Gyre Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2009 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Gyre Therapeutics Inc. ebitda for the quarter ending March 31, 2026 was -8.7 M, a 409.22% decrease year-over-year.
- Gyre Therapeutics Inc. ebitda for the twelve months ending March 31, 2026 was 9.6 M, a 119.62% decrease year-over-year.
- Gyre Therapeutics Inc. annual ebitda for 2025 was 14.0 M, a 21.14% decrease from 2024.
- Gyre Therapeutics Inc. annual ebitda for 2024 was 17.7 M, a 126.77% decrease from 2023.
- Gyre Therapeutics Inc. annual ebitda for 2023 was -66.2 M, a 742.92% decrease from 2022.
- Gyre Therapeutics Inc. annual ebitda for 2022 was 10.3 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Gyre Therapeutics Inc. EBITDA — FAQ
Gyre Therapeutics Inc. (GYRE) ebitda over the last 14 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see GYRE's ebitda history?
The chart and table above show Gyre Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.